These are the trials that are currently open in the Early Phase trials team (Last updated 16 May 2019).
| Trial Short Name | Molecular Target(s) | Patient Population | Lead Investigator(s) in Cambridge |
| AZD1390 | ATM with RT | Glioblastoma | S Jeffries / R Baird |
| AZD9833 ORAL SERD | ERα | ER positive, HER2 negative advanced breast cancer | R Baird |
| Basket of Baskets | PD-L1 | Solid tumours with high mutational load/MSI | R Baird |
| CALIBRATE | cfDNA evaluation | Patients on early phase clinical trials | R Baird / S Pacey |
| CALIBRATION | ctDNA evaluation | Advanced oesophageal malignancies | S Pacey |
| CamBMT1 phase II | EGFR/HER2 | Operable brain metastasis (breast/lung) | R Baird |
| CT7001 | CDK7 | Metastatic or locally advanced triple-negative breast cancer | R Baird |
| GO40782 | NTRK1/2/3 | Proven NTRK1/2/3 gene rearrangements | S Pacey |
| iBET | Bromodomain | Haematologic malignancies | B Huntly |
| LEAP-005 | PD-1 & RTK | Advanced TNBC, ovarian cancer, gastric cancer, colorectal cancer, GBM or BTC | B Basu |
| ONX-0801 | α-folate receptor | Platinum resistant ovarian cancer | B Basu |
| OUTREACH | CEBPα | Hepatocellular carcinoma | B Basu |
| PARADIGM 2 | PARP | Glioblastoma stratified by MGMT status | S Jeffries / R Baird |
| PATRIOT | ATR | Any tumour type – palliative radiotherapy combined with ATR inhibitor | R Baird |
| POSEIDON phase II | PI3K | HR+ metastatic breast cancer | R Baird |